Compounds > s20098
Page last updated: 2024-08-25

s20098 and Alloxan Diabetes

s20098 has been researched along with Alloxan Diabetes in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Ayar, A; Bulmus, FG; Bulmus, O; Canpolat, S; Etem, EO; Kelestimur, H; Oruc, S; Ozcan, M; Ozcan, S; Ulker, N; Yardimci, A1
Can, ÖD; Demir Özkay, Ü; Üçel, Uİ; Ulupınar, E1
Ayar, A; Bulmus, O; Canpolat, S; Kacar, E; Kelestimur, H; Ozcan, M; Ozcan, S; Serhatlioglu, I; Tekin, S; Tektemur, A; Ulker, N1
Aydın, TH; Can, ÖD; Demir Özkay, Ü; Turan, N1
Authier, N; Bertrand, M; Chapuy, E; Chenaf, C; Courteix, C; Eschalier, A; Gabriel, C; Libert, F; Marchand, F; Mocaër, E1

Other Studies

5 other study(ies) available for s20098 and Alloxan Diabetes

ArticleYear
Agomelatine potentiates anti-nociceptive effects of morphine in a mice model for diabetic neuropathy: involvement of NMDA receptor subtype NR1 within the raphe nucleus and periaqueductal grey.
    Neurological research, 2020, Volume: 42, Issue:7

    Topics: Acetamides; Analgesics; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drug Tolerance; Male; Mice; Mice, Inbred BALB C; Morphine; Periaqueductal Gray; Raphe Nuclei; Receptors, N-Methyl-D-Aspartate

2020
The Effect of Agomelatine Treatment on Diabetes-Induced Cognitive Impairments in Rats: Concomitant Alterations in the Hippocampal Neuron Numbers.
    International journal of molecular sciences, 2018, Aug-20, Volume: 19, Issue:8

    Topics: Acetamides; Animals; Cell Count; Cognitive Dysfunction; Diabetes Complications; Diabetes Mellitus, Experimental; Hippocampus; Male; Maze Learning; Memory; Neurons; Nootropic Agents; Rats, Sprague-Dawley

2018
Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin-induced diabetes in mice.
    Fundamental & clinical pharmacology, 2019, Volume: 33, Issue:2

    Topics: Acetamides; Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Blood Glucose; Brain; Brain Diseases; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Ganglia, Spinal; Hyperglycemia; Hypoglycemic Agents; Inflammation Mediators; Insulin; Interleukin-1beta; Male; Mice, Inbred BALB C; Neuroprotective Agents; Rats, Wistar; Receptors, Neurokinin-1; Streptozocin

2019
Effect of subacute agomelatine treatment on painful diabetic neuropathy: involvement of catecholaminergic mechanisms.
    Fundamental & clinical pharmacology, 2016, Volume: 30, Issue:6

    Topics: Acetamides; Animals; Blood Glucose; Catecholamines; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Fenclonine; Hyperalgesia; Hyperglycemia; Methyltyrosines; Neuralgia; Phentolamine; Propranolol; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Streptozocin

2016
Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence.
    Pain, 2017, Volume: 158, Issue:1

    Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Amines; Animals; Antineoplastic Agents; Constriction, Pathologic; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Disease Models, Animal; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Hypnotics and Sedatives; Idazoxan; Male; Motor Activity; Neuralgia; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Rats; Rats, Sprague-Dawley; Thiophenes

2017